Alan Watt PhD MBA is a biomedical entrepreneur working in inflammation research and is co-founder and Science Director of healthcare company XenoVida Limited
@CEOCorbus@DanielJDrucker Two reasons come to mind - 1) because chronic immunosuppressive drugs don’t get in the brain and 2) single cytokine targets are probably insufficient for efficacy.
@Kennydoesbio NLRP3 inhibition also phenocopies the Nlrp3 knockout which doesn’t gain weight on a high fat diet. In non-obese animals and presumably humans there is no weight loss and no formal obesity studies have been done in human for other NLRP3 inhibitors.
@Kennydoesbio Alan Watt from NodThera here. Dapansutrile doesn’t inhibit NLRP3. We’ve looked hard and it doesn’t, despite the claims. The other clinical NLRP3 compounds do not get into the brain. Reversal of hypothalamic inflammation is the key.